A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer

Figure 7

The HIF-1α protein expression of hepatoma tissue in the four groups on day 14 (×400 folds). (a) Control group; (b) UTMD group; (c) TAE group; (d) UTMD+TAE group.

(a)

(b)

(c)

(d)